抗毒素在炭疽病预防和治疗中的应用:系统综述
该研究检索11个数据库至2019年7月,纳入FDA批准用于人类、非人灵长类及兔的炭疽抗毒素研究。3种FDA批准抗毒素单药治疗在兔和非人灵长类中较安慰剂显著改善生存,但抗毒素联合抗菌药物较抗菌药物单药未见显著生存改善。25例系统性炭疽患者接受抗毒素治疗,17例存活。
要点
- 3种FDA批准抗毒素单药在兔和非人灵长类中较安慰剂显著改善生存。
- 抗毒素联合抗菌药物较抗菌药物单药未见显著生存改善。
- 25例系统性炭疽患者接受抗毒素治疗,17例存活。
核心结论
- 有限的人类和动物证据表明,辅助抗毒素治疗可能改善系统性炭疽感染的生存。
- 在可能涉及耐多药炭疽芽孢杆菌株的蓄意炭疽事件中,抗毒素也可作为抗菌药物的替代治疗或暴露后预防。
研究设计与样本
- 系统综述,检索11个数据库至2019年7月,并纳入12篇出版物和2篇病例报告。
主要发现
- 3种FDA批准的炭疽抗毒素单药治疗在兔和非人灵长类中较安慰剂显著改善生存。
- 抗毒素联合抗菌药物较抗菌药物单药未发现显著生存改善。
- 病例报告和病例系列描述了25例接受抗毒素治疗的系统性炭疽患者,其中17例存活。
- 使用抗毒素单药作为暴露后预防的动物研究显示较安慰剂显著改善生存,早期给药改善最大。
临床怎么用
- 有限的人类和动物证据表明,辅助抗毒素治疗可能改善系统性炭疽感染的生存。
- 在可能涉及耐多药炭疽芽孢杆菌株的蓄意炭疽事件中,抗毒素也可作为抗菌药物的替代治疗或暴露后预防。
局限性
- 有限的人类和动物证据表明,辅助抗毒素治疗可能改善系统性炭疽感染的生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bacillus anthracis is a high-priority threat agent because of its widespread availability, easy dissemination, and ability to cause substantial morbidity and mortality. Although timely and appropriate antimicrobial therapy can reduce morbidity and mortality, the role of adjunctive therapies continues to be explored. METHODS: We searched 11 databases for articles that report use of anthrax antitoxins in treatment or prevention of systemic anthrax disease published through July 2019. We identified other data sources through reference search and communication with experts. We included English-language studies on antitoxin products with approval by the US Food and Drug Administration (FDA) for anthrax in humans, nonhuman primates, and rabbits. Two researchers independently reviewed studies for inclusion and abstracted relevant data. RESULTS: We abstracted data from 12 publications and 2 case reports. All 3 FDA-approved anthrax antitoxins demonstrated significant improvement in survival as monotherapy over placebo in rabbits and nonhuman primates. No study found significant improvement in survival with combination antitoxin and antimicrobial therapy compared to antimicrobial monotherapy. Case reports and case series described 25 patients with systemic anthrax disease treated with antitoxins; 17 survived. Animal studies that used antitoxin monotherapy as postexposure prophylaxis (PEP) demonstrated significant improvement in survival over placebo, with greatest improvements coming with early administration. CONCLUSIONS: Limited human and animal evidence indicates that adjunctive antitoxin treatment may improve survival from systemic anthrax infection. Antitoxins may also provide an alternative therapy to antimicrobials for treatment or PEP during an intentional anthrax incident that could involve a multidrug-resistant B. anthracis strain.
引用
- Hesse EM, Godfred-Cato S, Bower WA, et al. Antitoxin Use in the Prevention and Treatment of Anthrax Disease: A Systematic Review. Clin Infect Dis. 2022. PMID: 36251559. doi:10.1093/cid/ciac532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。